Drugs / Gaviscon
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | GAVISCON | — | 1983-12-09 | fda.gov ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03069963 | Feb → Apr 2017 | gastroesophageal reflux disease | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03065816 | Feb → May 2017 | gastroesophageal reflux disease | Sanofi | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02783378 | Feb 2016 → Aug 2017 | gastroesophageal reflux disease | University Hospital Brussels | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gaviscon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03065816 ↗ |
| Route | Oral | “Route of administration: oral” NCT03065816 ↗ |